1 1 Bio-genics limited 03665155 false 2023-12-01 2024-08-31 2024-08-31 The principal activity of the company is Dormant Digita Accounts Production Advanced 6.30.9574.0 true 03665155 2023-12-01 2024-08-31 03665155 2024-08-31 03665155 core:RetainedEarningsAccumulatedLosses 2024-08-31 03665155 core:ShareCapital 2024-08-31 03665155 core:CurrentFinancialInstruments core:WithinOneYear 2024-08-31 03665155 core:OfficeEquipment 2024-08-31 03665155 bus:SmallEntities 2023-12-01 2024-08-31 03665155 bus:AuditExemptWithAccountantsReport 2023-12-01 2024-08-31 03665155 bus:FullAccounts 2023-12-01 2024-08-31 03665155 bus:SmallCompaniesRegimeForAccounts 2023-12-01 2024-08-31 03665155 bus:RegisteredOffice 2023-12-01 2024-08-31 03665155 bus:Director1 2023-12-01 2024-08-31 03665155 bus:PrivateLimitedCompanyLtd 2023-12-01 2024-08-31 03665155 bus:Agent1 2023-12-01 2024-08-31 03665155 core:ComputerEquipment 2023-12-01 2024-08-31 03665155 core:OfficeEquipment 2023-12-01 2024-08-31 03665155 countries:AllCountries 2023-12-01 2024-08-31 03665155 2023-11-30 03665155 core:OfficeEquipment 2023-11-30 03665155 2022-12-01 2023-11-30 03665155 2023-11-30 03665155 core:RetainedEarningsAccumulatedLosses 2023-11-30 03665155 core:ShareCapital 2023-11-30 03665155 core:CurrentFinancialInstruments core:WithinOneYear 2023-11-30 03665155 core:OfficeEquipment 2023-11-30 xbrli:pure iso4217:GBP

Registration number: 03665155

Bio-genics limited

Annual Report and Unaudited Financial Statements

for the Period from 1 December 2023 to 31 August 2024

 

Bio-genics limited

Contents

Company Information

1

Director's Report

2

Accountants' Report

3

Statement of Comprehensive Income

4

Statement of Financial Position

5

Notes to the Unaudited Financial Statements

6 to 8

Detailed Statement of Comprehensive Income

9

 

Bio-genics limited

Company Information

Director

Mr P Collins

Registered office

83 High Street
West Wickham
Kent
BR4 0LS

Accountants

Sherwoods
Chartered Certified Accountants83 High Street
West Wickham
Kent
BR4 0LS

 

Bio-genics limited

Director's Report for the Period from 1 December 2023 to 31 August 2024

The director presents his report and the financial statements for the period from 1 December 2023 to 31 August 2024.

Director of the company

The director who held office during the period was as follows:

Mr P Collins

Small companies provision statement

This report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

Approved and authorised by the director on 14 May 2025
 


Mr P Collins
Director

 

Chartered Certified Accountants' Report to the Director on the Preparation of the Unaudited Statutory Accounts of
Bio-genics limited
for the Period Ended 31 August 2024

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Bio-genics limited for the period ended 31 August 2024 as set out on pages 4 to 8 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at https://www.accaglobal.com/gb/en/member/standards/rules-and-standards/rulebook.html.

This report is made solely to the Board of Directors of Bio-genics limited, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of Bio-genics limited and state those matters that we have agreed to state to the Board of Directors of Bio-genics limited, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/gb/en/technical-activities/technical-resources-search/2009/
october/factsheet-163-audit-exempt-companies.html. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Bio-genics limited and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Bio-genics limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and loss of Bio-genics limited. You consider that Bio-genics limited is exempt from the statutory audit requirement for the period.

We have not been instructed to carry out an audit or a review of the accounts of Bio-genics limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

Sherwoods
Chartered Certified Accountants
83 High Street
West Wickham
Kent
BR4 0LS

14 May 2025

 

Bio-genics limited

Statement of Comprehensive Income for the Period from 1 December 2023 to 31 August 2024

Note

2024
£

2023
£

Turnover

 

12,060

7,752

Cost of sales

 

(74)

(532)

Gross profit

 

11,986

7,220

Administrative expenses

 

(11,999)

(7,295)

Operating loss

 

(13)

(75)

Loss before tax

4

(13)

(75)

Loss for the financial period

 

(13)

(75)

The above results were derived from continuing operations.

The company has no recognised gains or losses for the period other than the results above.

 

Bio-genics limited

(Registration number: 03665155)
Statement of Financial Position as at 31 August 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

5

-

48

Current assets

 

Cash at bank and in hand

 

8,267

6,241

Creditors: Amounts falling due within one year

6

(8,105)

(6,114)

Net current assets

 

162

127

Net assets

 

162

175

Capital and reserves

 

Called up share capital

2

2

Profit and loss account

160

173

Shareholders' funds

 

162

175

For the financial period ending 31 August 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’.

Approved and authorised by the director on 14 May 2025
 


Mr P Collins
Director

 

Bio-genics limited

Notes to the Unaudited Financial Statements for the Period from 1 December 2023 to 31 August 2024

1

General information

The company is a private company limited by share capital, incorporated in United Kingdon.

The address of its registered office is:
83 High Street
West Wickham
Kent
BR4 0LS
England

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The financial statements are prepared in sterling which is the functional currency of the entity.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

 

Bio-genics limited

Notes to the Unaudited Financial Statements for the Period from 1 December 2023 to 31 August 2024

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Computer equipment

25% on reducing balance

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value. In the statement of financial position, bank overdrafts are shown within borrowing or current liabilities

Financial instruments

Recognition and measurement
A financial asset or a financial liability is recognised only when the company becomes party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

3

Staff numbers

The average number of persons employed by the company (including the director) during the period, was 1 (2023 - 1).

4

Loss before tax

Arrived at after charging/(crediting)

2024
£

2023
£

Depreciation expense

48

16

 

Bio-genics limited

Notes to the Unaudited Financial Statements for the Period from 1 December 2023 to 31 August 2024

5

Tangible assets

Office equipment
£

Total
£

Cost or valuation

At 1 December 2023

1,157

1,157

At 31 August 2024

1,157

1,157

Depreciation

At 1 December 2023

1,109

1,109

Charge for the period

48

48

At 31 August 2024

1,157

1,157

Carrying amount

At 31 August 2024

-

-

At 30 November 2023

48

48

6

Creditors

Creditors: amounts falling due within one year

2024
£

2023
£

Due within one year

Accruals and deferred income

4,500

2,580

Other creditors

3,605

3,534

8,105

6,114

7

Reserves

Profit and loss account:

This reserve records retained earnings and accumulated losses.

 

Bio-genics limited

Detailed Statement of Comprehensive Income for the Period from 1 December 2023 to 31 August 2024

2024
£

2023
£

Turnover

Fees and commission received

12,060

7,752

12,060

7,752

Cost of sales

Medical supplies

74

532

74

532

Gross profit

11,986

7,220

Gross profit (%)

99.39%

93.14%

Administrative expenses

Wages

2,500

650

Insurance

562

627

Use of residence as office

600

600

Telephone

521

489

Postage, stationery & advertising

21

344

Sundry expenses

356

-

Motor expenses

2,517

1,415

Traveling

400

12

Accountancy fees

1,600

1,260

Consultancy

980

-

Professional fees

1,676

1,690

Bank charges

218

192

Depreciation of computer equipment

48

16

11,999

7,295

Operating loss

(13)

(75)

Loss before tax

(13)

(75)